Rafael Pharmaceuticals Announces Expansion into France of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer September 17, 2019 - NYSE Companies 0 » View More News for September 17, 2019